about
Effect of Statin Use on Influenza Vaccine Effectiveness.School absenteeism among school-aged children with medically attended acute viral respiratory illness during three influenza seasons, 2012-2013 through 2014-2015.What patients think doctors know: beliefs about provider knowledge as barriers to safe medication useDisparities in mortality rates among US infants born late preterm or early term, 2003-2005.Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy.Variability in Acetaminophen Labeling Practices: a Missed Opportunity to Enhance Patient Safety.Risk of unintentional overdose with non-prescription acetaminophen products.Usability of FDA-approved medication guides.Risk of anaphylaxis after vaccination in children and adultsTake-Wait-Stop: a patient-centered strategy for writing PRN medication instructionsEHR-based medication support and nurse-led medication therapy management: rationale and design for a three-arm clinic randomized trial.Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.Patient recall of health care provider counseling for opioid-acetaminophen prescriptions.Influenza and Workplace Productivity Loss in Working Adults.Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations.Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12.An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.Developing consumer-centered, nonprescription drug labeling a study in acetaminophen.Validation of self-reported influenza vaccination in the current and prior season
P50
Q30391150-AE393125-8737-49B1-9932-6BADAB12BF3AQ33619841-587AEAF4-B3D5-4762-A9C5-BC22CE2BD85EQ33697039-D73545DC-139B-46B7-9536-018640FCB809Q35530046-59599BED-C3CE-4A91-A058-6E4136CADF71Q36201827-1DD12215-C23C-4B70-9090-281A87FD409CQ36362741-6ADF26DE-E067-4389-8794-7E17D6F8A69AQ36431523-B151C92E-9C08-4DED-A9BD-AA7542A19A6AQ36431589-BC620D3B-2529-4503-8B92-57A6F3A05A7CQ36665226-6EA4F719-E41F-421E-AF00-15C7D525D444Q37272568-82AC3BC1-C48A-4DE9-991E-4E837DD549D4Q37328765-3328BCC6-592F-407D-9DC6-987A4C8C0A93Q38803189-1BA51DAE-C6E7-4C7B-B845-0F88E9DD1240Q39157521-45492881-32A3-4813-83DA-3FEFB77266B3Q40101305-3915E702-3232-419E-A7A9-D30C332C01D5Q40133941-BD278EEF-803E-4D7D-B1C3-2E6826500A99Q40891787-F4252FC6-D063-44B1-9931-1414C6D1A537Q46542124-935748A0-6BE9-4892-BD37-3F6C5A0931D9Q49713969-7442AF11-F33B-47B5-A57A-37A97470AF8EQ50208587-DAD01CA8-DBC5-4052-A856-9332BC2816D7Q51867598-2F64EF03-6EB6-4549-A9FA-11AF09773723Q58779405-72553E6D-619B-4C0E-82E4-C9BBDC912FEC
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jennifer P King
@ast
Jennifer P King
@en
Jennifer P King
@es
Jennifer P King
@nl
type
label
Jennifer P King
@ast
Jennifer P King
@en
Jennifer P King
@es
Jennifer P King
@nl
prefLabel
Jennifer P King
@ast
Jennifer P King
@en
Jennifer P King
@es
Jennifer P King
@nl
P106
P21
P31
P496
0000-0003-4627-1378